Compounds having the formula I wherein R
1
, R
2
, R
3
, R
4a
, R
4b
, R
4c
, R
5
, R
6
, R
9
and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.